1/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/15
09:15 am
stok
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Medium
Report
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
1/12
09:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
1/11
02:13 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
1/11
02:00 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
1/6
04:01 pm
stok
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
08:33 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
1/5
08:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
1/5
07:17 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
12/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
12/15
10:58 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
12/15
09:04 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.
12/10
09:32 pm
stok
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]
Medium
Report
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]
12/6
07:29 pm
stok
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]
Medium
Report
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]
12/5
09:40 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
12/5
09:00 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
12/4
05:12 pm
stok
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
Low
Report
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
12/1
07:30 am
stok
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
11/28
10:18 am
stok
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
Low
Report
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
11/21
05:31 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/18
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
11/17
07:30 am
stok
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Low
Report
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
11/10
01:17 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.
11/5
04:01 pm
stok
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
11/5
12:11 pm
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $28.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $28.00 price target on by analysts at Canaccord Genuity Group Inc..